Fixed-dose combination therapy in type 2 diabetes mellitus

Endocrine Practice

Volumn 20, Issue 12, 2014, Pages 1322-1332

  Blonde, Lawrence ^a   Juan, Zinnia T San ^b   Bolton, Peggy ^a  

^a OCHSNER MEDICAL CENTER   (United States)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALOGLIPTIN PLUS METFORMIN; GLIBENCLAMIDE PLUS METFORMIN; GLIPIZIDE PLUS METFORMIN; LINAGLIPTIN PLUS METFORMIN; METFORMIN; METFORMIN PLUS PIOGLITAZONE; METFORMIN PLUS REPAGLINIDE; METFORMIN PLUS ROSIGLITAZONE; METFORMIN PLUS SAXAGLIPTIN; METFORMIN PLUS SITAGLIPTIN;

ABDOMINAL PAIN; BACKACHE; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG TOLERABILITY; DYSPEPSIA; EDEMA; GASTROINTESTINAL SYMPTOM; HEADACHE; HEALTH CARE COST; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOGLYCEMIA; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PERIPHERAL EDEMA; PILL; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SINUSITIS; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOMITING;

EID: 84919966886     PISSN: 1530891X     EISSN: 19342403     Source Type: Journal    
DOI: 10.4158/EP14259.RA     Document Type: Review

References (69)

1. DeFronzo R. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58:773-795.
2. Davidson JA. Advances in therapy for type 2 diabetes: GLP-1 receptor agonists and DPP-4 inhibitors. Cleve Clin J Med. 2009;76 Suppl 5:S28-38.
3. Vilsbøll T, Krarup T, Madsbad S, Holst JJ. Defective amplification of the late phase insulin response to glucose by GIP in obese type II diabetic patients. Diabetologia. 2002;45:1111-1119.
4. Nauck MA, Vardarli I, Deacon CF, Holst JJ, Meier JJ. Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down? Diabetologia. 2011;54: 10-18.
5. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 1999;281: 2005-2012.
6. Brown JB, Nichols GA, Perry A. The burden of treatment failure in type 2 diabetes. Diabetes Care. 2004;27: 1535-1540.
7. Riedel AA, Heien H, Wogen J, Plauschinat CA. Loss of glycemic control in patients with type 2 diabetes mellitus who were receiving initial metformin, sulfonylurea, or thiazolidinedione monotherapy. Pharmacotherapy. 2007;27: 1102-1110.
8. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35: 1364-1379.
9. Garber AJ, Abrahamson MJ, Barzilay JI, et al. AACE Comprehensive Diabetes Management Algorithm 20. Endocr Pract. 2013;19:327-336.
10. Hollander PA, Kushner P. Type 2 diabetes comorbidities and treatment challenges: rationale for DPP-4 inhibitors. Postgrad Med. 2010;122:71-80.
11. Huang ES, Karter AJ, Danielson KK, Warton EM, Ahmed AT. The association between the number of prescription medications and incident falls in a multi-ethnic population of adult type-2 diabetes patients: the Diabetes and Aging Study. J Gen Intern Med. 2010;25:141-146.
12. Mizokami F, Koide Y, Noro T, Furuta K. Polypharmacy with common diseases in hospitalized elderly patients. Am J Geriatr Pharmacother. 2012;10:123-128.
13. van Bruggen R, Gorter K, Stolk RP, Zuithoff P, Klungel OH, Rutten GE. Refill adherence and polypharmacy among patients with type 2 diabetes in general practice. Pharmacoepidemiol Drug Saf. 2009;18:983-991.
14. Donnan PT, MacDonald TM, Morris AD. Adherence to prescribed oral hypoglycaemic medication in a population of patients with type 2 diabetes: a retrospective cohort study. Diabet Med. 2002;19:279-284.
15. Giannarelli R, Aragona M, Coppelli A, Del Prato S. Reducing insulin resistance with metformin: the evidence today. Diabetes Metab. 2003;29:6S28-35.
16. Hundal RS, Krssak M, Dufour S, et al. Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes. 2000;49:2063-2069.
17. Glucophage® and Glucophage XR® (metformin HCl tablets and metformin HCl extended-release tablets). Full Prescribing Information, Bristol-Myers Squibb Company, Princeton, NJ, 2009.
18. Mannucci E, Ognibene A, Cremasco F, et al. Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects. Diabetes Care. 2001; 24:489-494.
19. Mulherin AJ, Oh AH, Kim H, Grieco A, Lauffer LM, Brubaker PL. Mechanisms underlying metformin-induced secretion of glucagon-like peptide-1 from the intestinal L cell. Endocrinology. 2011;152:4610-4619.
20. Florez H, Luo J, Castillo-Florez S, et al. Impact of metformin-induced gastrointestinal symptoms on quality of life and adherence in patients with type 2 diabetes. Postgrad Med. 2010;122:112-120.
21. GLUMETZA (metformin hydrochloride extended release). Full Prescribing Information, Depomed, Inc., Menlo Park, CA, 2008.
22. Glucophage (metformin hydrochloride) and Glucophage XR (metformin hydrochloride extended-release). Full Prescribing Information, Bristol-Myers Squibb Company, Princeton, NJ, 2009.
23. FORTAMET (metformin hydrochloride). Full Prescribing Information, Shionogi Pharma, Inc., Atlanta, GA, 2010.
24. Filion KB, Joseph L, Boivin JF, Suissa S, Brophy JM. Trends in the prescription of anti-diabetic medications in the United Kingdom: a population-based analysis. Pharmacoepidemiol Drug Saf. 2009;18:973-976.
25. Johnson JA, Pohar SL, Secnik K, Yurgin N, Hirji Z. Utilization of diabetes medication and cost of testing supplies in Saskatchewan, 20. BMC Health Serv Res. 2006; 6:159.
26. Yurgin N, Secnik K, Lage MJ. Antidiabetic prescriptions and glycemic control in German patients with type 2 diabetes mellitus: a retrospective database study. Clin Ther. 2007;29:316-325.
27. AVANDAMET (rosiglitazone maleate and metformin hydrochloride). Full Prescribing Information, GlaxoSmithKline, Research Triangle Park, NC, 2008.
28. METAGLIP (glipizide and metformin hydrochloride). Full Prescribing Information, Bristol-Myers Squibb, Princeton, NJ, 2009.
29. ACTOPLUS MET® (pioglitazone hydrochloride and metformin hydrochloride) and ACTOPLUS MET XR® (pioglitazone hydrochloride and metformin hydrochloride extended-release). Full Prescribing Information, Takeda Pharmaceuticals America, Inc., Deerfield, IL, 2010.
30. GLUCOVANCE (glyburide and metformin hydrochloride). Full Prescribing Information, Bristol-Myers Squibb Company, Princeton, NJ, 2010.
31. JANUMET (sitagliptin/metformin hydrochloride). Full Prescribing Information, Merck & Co., Inc., Whitehouse Station, NJ, 2010.
32. PRANDIMET (repaglinide/metformin HCl). Full Prescribing Information, Novo Nordisk, Princeton, NJ, 2011.
33. KAZANO (alogliptin and metformin HCl tablets). Full Prescribing Information, Takeda Pharmaceuticals America, Inc., Deerfield, IL, 2013.
34. JENTADUETO (linagliptin/metformin HCl). Full Prescribing Information, Boehringer Ingleheim Pharmaceuticals, Inc., Ridgefield, CT, 2012.
35. KOMBIGLYZE XR (saxagliptin and metformin hydrochloride extended release). Full Prescribing Information, Bristol-Myers Squibb, Princeton, NJ, 2011.
36. JANUMET® XR (sitagliptin/metformin HCl extendedrelease). Full Prescribing Information, Merck & Co., Inc., Whitehouse Station, NJ, 2012.
37. U.S. Food and Drug Administration. Label and approval history: Glucophage. Available at: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index. cfm?fuseaction=Search.Label-ApprovalHistory#apphist. Accessed August 12, 2014.
38. U.S. Food and Drug Administration. Drug approval package: Glucophage XR (metformin hydrochloride) extended release tablets. U.S. Department of Health & Human Services, 2003.
39. Timmins P, Donahue S, Meeker J, Marathe P. Steadystate pharmacokinetics of a novel extended-release metformin formulation. Clin Pharmacokinet. 2005;44:721-729.
40. Gao H, Xiao W, Wang C, et al. The metabolic effects of once daily extended-release metformin in patients with type 2 diabetes: a multicentre study. Int J Clin Pract. 2008;62: 695-700.
41. Schwartz S, Fonseca V, Berner B, Cramer M, Chiang YK, Lewin A. Efficacy, tolerability, and safety of a novel once-daily extended-release metformin in patients with type 2 diabetes. Diabetes Care. 2006;29:759-764.
42. Blonde L, Dailey GE, Jabbour SA, Reasner CA, Mills DJ. Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: results of a retrospective cohort study. Curr Med Res Opin. 2004;20:565-572.
43. Davidson J, Howlett H. New prolonged-release metformin improves gastrointestinal tolerability. Br J Diabetes Vasc Dis. 2004;4:273-277.
44. Blonde L, Wogen J, Kreilick C, Seymour AA. Greater reductions in A1C in type 2 diabetic patients new to therapy with glyburide/metformin tablets as compared to glyburide co-Administered with metformin. Diabetes Obes Metab. 2003;5:424-431.
45. Pan F, Chernew ME, Fendrick AM. Impact of fixed-dose combination drugs on adherence to prescription medications. J Gen Intern Med. 2008;23:611-614.
46. Thayer S, Arondekar B, Harley C, Darkow TE. Adherence to a fixed-dose combination of rosiglitazone/glimepiride in subjects switching from monotherapy or dual therapy with a thiazolidinedione and/or a sulfonylurea. Ann Pharmacother. 2010;44:791-799.
47. Cheong C, Barner JC, Lawson KA, Johnsrud MT. Patient adherence and reimbursement amount for antidiabetic fixed-dose combination products compared with dual therapy among Texas Medicaid recipients. Clin Ther. 2008;30:1893-1907.
48. Melikian C, White TJ, Vanderplas A, Dezii CM, Chang E. Adherence to oral antidiabetic therapy in a managed care organization: a comparison of monotherapy, combination therapy, and fixed-dose combination therapy. Clin Ther. 2002;24:460-467.
49. Paes AH, Bakker A, Soe-Agnie CJ. Impact of dosage frequency on patient compliance. Diabetes Care. 1997;20:1512-1517.
50. Kardas P. The DIACOM study (effect of DosIng frequency of oral Antidiabetic agents on the COMpliance and biochemical control of type 2 diabetes). Diabetes Obes Metab. 2005;7:722-728.
51. Pollack MF, Purayidathil FW, Bolge SC, Williams SA. Patient-reported tolerability issues with oral antidiabetic agents: associations with adherence; treatment satisfaction and health-related quality of life. Diabetes Res Clin Pract. 2010;87:204-210.
52. Breitscheidel L, Stamenitis S, Dippel FW, Schöffski O. Economic impact of compliance to treatment with antidiabetes medication in type 2 diabetes mellitus: a review paper. J Med Econ. 2010;13:8-15.
53. Hansen RA, Farley JF, Droege M, Maciejewski ML. A retrospective cohort study of economic outcomes and adherence to monotherapy with metformin, pioglitazone, or a sulfonylurea among patients with type 2 diabetes mellitus in the United States from 2003 to 2005. Clin Ther. 2010;32:1308-1319.
54. Hepke KL, Martus MT, Share DA. Costs and utilization associated with pharmaceutical adherence in a diabetic population. Am J Manag Care. 2004;10:144-151.
55. Salas M, Hughes D, Zuluaga A, Vardeva K, Lebmeier M. Costs of medication nonadherence in patients with diabetes mellitus: a systematic review and critical analysis of the literature. Value Health. 2009;12:915-922.
56. Asche C, LaFleur J, Conner C. A review of diabetes treatment adherence and the association with clinical and economic outcomes. Clin Ther. 2011;33:74-109.
57. Hutchins V, Zhang B, Fleurence RL, Krishnarajah G, Graham J. A systematic review of adherence, treatment satisfaction and costs, in fixed-dose combination regimens in type 2 diabetes. Curr Med Res Opin. 2011;27:1157-1168.
58. AVANDARYL (rosiglitazone maleate and glimepiride). Full Prescribing Information, GlaxoSmithKline, Research Triangle Park, NC, 2009.
59. DUETACT (pioglitazone hydrochloride and glimepiride). Full Prescribing Information, Takeda Pharmaceuticals America, Inc., Deerfield, IL, 2009.
60. OSENI (alogliptin and pioglitazone tablets). Full Prescribing Information, Takeda Pharmaceuticals America, Inc., Deerfield, IL, 2013.
61. Blonde L, San Juan ZT. Fixed-dose combinations for treatment of type 2 diabetes mellitus. Adv Ther. 2012;29:1-13.
62. Stenlöf K, Raz I, Neutel J, Ravichandran S, Berglind N, Chen R. Saxagliptin and metformin XR combination therapy provides glycemic control over 24 hours in patients with T2DM inadequately controlled with metformin. Curr Med Res Opin. 2010;26:2355-2363.
63. Fonseca V, Zhu T, Karyekar C, Hirshberg B. Adding saxagliptin to extended-release metformin vs. uptitrating metformin dosage. Diabetes Obes Metab. 2012;14:365-371.
64. Dormandy J, Bhattacharya M, van Troostenburg de Bruyn AR, PROactive investigators. Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive. Drug Saf. 2009; 32:187-202.
65. Piccinni C, Motola D, Marchesini G, Poluzzi E. Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting. Diabetes Care. 2011;34:1369-1371.
66. Lewis JD, Ferrara A, Peng T, et al. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care. 2011; 34:916-922.
67. Johnson & Johnson. Janssen research & development submits new drug application to U.S. FDA for canagliflozin/metformin fixed-dose combination therapy to treat patients with type 2 diabetes. Available at: http://www.investor. jnj.com/releasedetail.cfm?ReleaseID=7263. Accessed August 12, 2014.
68. AstraZeneca and Bristol-Myers Squibb. To compare the similarity of a combination dapagliflozin/metformin tablet with the two drugs administered separately. Available at: http://clinicaltrials.gov/ct2/show/NCT01535677?term= dapagliflozin+metformin+fixed+dose&rank=4. Accessed August 12, 2014.
69. Boehringer Ingelheim Pharmaceuticals. Bioequivalence of a fixed dose combination tablet linagliptin/pioglitazone compared with its mono-components. Available at: http://clinicaltrials.gov/ct2/show/NCT01276327?term=fixed+do se+linagliptin+pioglitazone&rank=1. Accessed August 12, 2014.